leadf
logo-loader
viewAgile Therapeutics

Agile Therapeutics gets FDA new drug application acceptance for its contraceptive patch

Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari tells Proactive Investors the FDA has accepted for review its new drug application resubmission for Twirla, its low-dose combined hormonal contraceptive patch.

Altomari says this was a big day for the company, and looks forward to the assigned Prescription Drug User Fee Act (PDUFA) goal date of November 16, 2019.

Quick facts: Agile Therapeutics

Price: 3.02 USD

NASDAQ:AGRX
Market: NASDAQ
Market Cap: $254.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Agile Therapeutics commercially launches its women's contraceptive patch...

Agile Therapeutics, Inc. (NASDAQ:AGRX) CEO Al Altomari tells Proactive the Princeton, New Jersey-based women’s healthcare company has commercially launched its low-dose, non-daily contraceptive patch for women named Twirla. Altomari says the group has built a system that can adapt to business...

on 12/09/2020

2 min read